Compare Cipher Mining Inc (CIFR) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cipher Mining Inc vs Gilead Sciences, Inc. — how do they compare? Cipher Mining Inc trades at $18.91 (market cap $8.13B), while Gilead Sciences, Inc. trades at $132.39 (market cap $161.45B). The key difference: Gilead Sciences, Inc. is far larger — about 19.9× Cipher Mining Inc's market cap, and Gilead Sciences, Inc. pays a 2.52% dividend while Cipher Mining Inc pays none. Which is the better fit depends on your goals.
| CIFR | GILD | |
|---|---|---|
Market Cap | $8.13B | $161.45B |
Sector | Basic Materials | Health |
52-Week High | $29.18 | $155.80 |
52-Week Low | $4.72 | $108.22 |
Enterprise Value | $12.16B | $175.98B |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIFR trades at $20.085, down 9.16% over 24 hours, reflecting bearish technical signals despite unanimous analyst buy ratings. The company is transitioning from Bitcoin mining to AI data center operations, evidenced by a $11.4B contracted revenue backlog but faces significant financial strain with a -427.79% net income margin and negative cash flow from operations. Recent news highlights volatility driven by AI infrastructure developments and capital raises.
The outlook hinges on successful execution of its AI data center pivot, offering substantial upside to the $32.81 consensus price target, but high valuation multiples and persistent losses pose near-term risks. Investors must weigh transformative growth potential against cash burn and execution challenges in a competitive sector.
Gilead Sciences (GILD) trades at $131.40, up 1.21% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA approvals for Trodelvy in metastatic triple-negative breast cancer and ongoing Ebola antiviral trials highlight pipeline strength. Analyst consensus remains strongly positive with a $152.83 price target.
GILD presents a compelling investment case with strong profitability, expanding oncology portfolio, and 67% analyst buy ratings. Key risks include patent expirations on HIV drugs and volatile cash flow trends. The stock offers 16% upside to consensus target with dividend support, though investors should monitor pipeline execution and generic competition timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cipher Mining Inc
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
